Belvedere Trading’s Lunai Bioworks LNAI Stock Holding History

Belvedere Trading’s Portfolio LNAI Stock Details LNAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-304	Closed	-$25K	–	1351
2022 Q4	$25K	Buy	+304	New	+$40.8K	﹤0.01%	789

Other funds holding LNAI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Belvedere Trading's LNAI Position: Q1 2023 in Review

Belvedere Trading sold out of Lunai Bioworks (LNAI) in Q1 2023, closing a stake of 295 shares — an estimated $24.3K sold.

Belvedere Trading first reported a position in LNAI in Q4 2022 and held it in 1 quarter. The position peaked at $24.3K in Q4 2022. 40 funds tracked by Wall St. Rank hold LNAI as of Q1 2023.

Belvedere Trading reported no remaining Lunai Bioworks position as of Q1 2023 after selling out during the quarter.
Belvedere Trading sold 295 Lunai Bioworks shares in Q1 2023, an estimated $24.3K.
Belvedere Trading first reported a position in Lunai Bioworks in Q4 2022 and held it in 1 quarter.
Belvedere Trading's Lunai Bioworks position peaked at $24.3K in Q4 2022.
40 funds tracked by Wall St. Rank held Lunai Bioworks as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.